Abstract 46P
Background
Lenvatinib has been identified as a multikinase inhibitor with the effect of inhibiting angiogenesis for advanced ICC. This study aimed to compare the efficacy and safety of GEMOX and PD-1 inhibitors combined with or without lenvatinib as first-line therapy for advanced ICC.
Methods
Eligible participants with treatment naive and diagnosis of unresectable advanced ICC were assigned to G-P-L group: gemcitabine (1000 mg/m2on days 1 and 8 every 3 weeks), oxaliplatin (85 mg/m2on day 1 every 3 weeks), PD-1 inhibitors and lenvatinib (12 mg for weight ≥ 60 kg or 8 mg for weight < 60 kg, once daily), and G-P group: gemcitabine, oxaliplatin and PD-1 inhibitors. The primary endpoints was to assess objective response rate (ORR) evaluated with mRECIST 1.1 and adverse events (AEs). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Genetic mutation biomarkers for lenvatinib were explored using WES.
Results
77 patients were enrolled and divided into G-P-L group (n=38) and G-P group (n=39). The median follow-up time was 23 months. The median PFS were 13 months in the G-P-L group and 7.9 months in the G-P group (hazard ratio[HR]: 0.38, 95% CI: 0.20–0.71, P=0.007). The median OS were 18.5 months in the G-P-L group and 14.6 months in the G-P group (P=0.19). No significant differences of grade ≥ 3 AEs were found between the G-P-L group and the G-P group (68.4% and 64.1%). ORR, DCR were 39.5% and 89.5% in the G-P-L group versus 33.3% and 76.9% in the G-P group, respectively. Multivariate Cox regression analysis indicated that with or without Lenvatinib combination was the independent risk factor of PFS in the entire group (P=0.002). Keap-1 gene mutation was found with significant difference in PR group comparing with SD and PD group in the G-P-L group (P=0.003).
Conclusions
GEMOX combined with PD-1 inhibitor and lenvatinib indicated the feasibility as first-line therapy for advanced ICC with Keap-1 gene mutation. Multi-center with large scale of cases study were needed for further exploration.
Clinical trial identification
NCT05215665.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1988P - Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study
Presenter: Tanya Jindal
Session: Poster session 13
1989P - Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis
Presenter: Albert Jang
Session: Poster session 13
1990P - MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study
Presenter: Chuanliang Cui
Session: Poster session 13
1992P - Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)
Presenter: Hedyeh Ebrahimi
Session: Poster session 13
1993P - A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
Presenter: Anishka D'Souza
Session: Poster session 13
1994P - Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Poster session 13
1995P - Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 13
1996P - Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan
Presenter: Eiji Kikuchi
Session: Poster session 13
1997P - Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Poster session 13